Navigation Links
NARSAD Introduces 'Healthy Minds Across America,' an International Event Recognizing the Toll of Mental Illness, on Sunday, Sept. 14
Date:8/26/2008

Featuring 48 Free Public Forums across U.S. and Canada on Progress and

Promise of Mental Health Research

GREAT NECK, N.Y., Aug. 26 /PRNewswire/ -- People concerned about the toll that mental health disorders are taking on their families and communities will have a unique opportunity to hear from world-class experts on what is known to-date about the causes, symptoms and progression of such illnesses as depression, bipolar disorder, anxiety, schizophrenia and autism, and learn about current and potential treatments.

In an unprecedented event called Healthy Minds Across America, 48 free public forums will take place around the United States and in Canada -- all on Sunday, September 14 -- at which some of the greatest minds and talents in neuropsychiatric research will report on the state of mental health research and how breakthroughs over the last 20 years have led to progress and hope, while uncovering new challenges.

NARSAD, the world's leading charity dedicated to mental health research, has organized Healthy Minds Across America, which is being held in partnership with many of North America's most prominent universities and research centers -- from multiple branches of the University of California and University of Texas to Yale, Harvard, the University of Pittsburgh, Duke and the University of Toronto, among dozens more.

"Never, to my knowledge, has there been such a concerted effort to bring the public together with the experts who hold the most knowledge about an area of human illness that accounts for more loss and devastation than any other," said Herbert Pardes, M.D., president of NARSAD's Scientific Council, who is also president and CEO of New York-Presbyterian Hospital and a former head of the National Institute of Mental Health. "Mental illness is so prevalent in our society, estimated to affect as many as one in four North Americans in any given year, with one in 10 suffering serious, chronic con
'/>"/>

SOURCE NARSAD
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NARSAD researchers identify specific genes and family traits linked to mental illnesses
2. Ezra Susser, MD, DrPH, receives Distinguished Investigator Award from NARSAD
3. NARSADs 5th Annual Mission Possible Symposium Offers Insight to PTSD and Other Mental Illnesses
4. NARSAD - the Worlds Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th
5. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
6. CytoViva(R) Introduces Breakthrough Nano-Technology Research Tool
7. ORSupply.com Introduces New Line of Products from Flexicare
8. STEMCELL Technologies Introduces AggreWell™400 for Standardized Embryonic Stem Cell and Induced Pluripotent Stem Cell Research
9. Gerbig Engineering Introduces New Product Feature
10. Resolution Health Introduces Womens Health and Wellness Action Campaign
11. JUVA Skin & Laser Center Introduces Affirm CO2 to New York City Laser Resurfacing Clients
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:More women with early-stage breast cancer choosing double mastectomies 2Health News:HealthMapRx, Mirixa and the City of Asheville Announce New Partnership to Improve Health & Healthcare Savings of Beneficiaries With Chronic Diseases 2Health News:HealthMapRx, Mirixa and the City of Asheville Announce New Partnership to Improve Health & Healthcare Savings of Beneficiaries With Chronic Diseases 3Health News:Nuvilex, Inc. Announces Investor Conference Call and Open House 2Health News:Nuvilex, Inc. Announces Investor Conference Call and Open House 3Health News:Children's Home + Aid Faces Revenue Shortfall 2Health News:Lifeclinic Names New Executive Vice President as its Presence in Non-Retail Wellness Sector Grows 2Health News:Nuvilex, Inc.'s Marketing Partner, CK41 to Launch purEffect(TM) in May 2Health News:Nuvilex, Inc.'s Marketing Partner, CK41 to Launch purEffect(TM) in May 3Health News:Nuvilex, Inc.'s Marketing Partner, CK41 to Launch purEffect(TM) in May 4Health News:Nuvilex, Inc.'s Marketing Partner, CK41 to Launch purEffect(TM) in May 5
Breaking Medicine Technology:National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2PRA International Hosts an Infectious Diseases Audio Conference 2PRA International Hosts an Infectious Diseases Audio Conference 3The Westin Kierland Resort And Mayo Clinic Present 26quot 3BWell Beyond 26quot 3B Weekend 47697 1The Westin Kierland Resort And Mayo Clinic Present 26quot 3BWell Beyond 26quot 3B Weekend 47697 2The Westin Kierland Resort And Mayo Clinic Present 26quot 3BWell Beyond 26quot 3B Weekend 47697 3The Westin Kierland Resort And Mayo Clinic Present 26quot 3BWell Beyond 26quot 3B Weekend 47697 4Network Merchants Inc 28NMI 29 Founders Donate 2450 000 to Schaumburgs Childrens Home 26 Aid 47692 1Network Merchants Inc 28NMI 29 Founders Donate 2450 000 to Schaumburgs Childrens Home 26 Aid 47692 2Photos 3A Philips Expands Home Healthcare Commitment With Portable Life Support Ventilator 3B Offers Ease of Use Portability and Versatility for Pati 47687 1Photos 3A Philips Expands Home Healthcare Commitment With Portable Life Support Ventilator 3B Offers Ease of Use Portability and Versatility for Pati 47687 2Photos 3A Philips Expands Home Healthcare Commitment With Portable Life Support Ventilator 3B Offers Ease of Use Portability and Versatility for Pati 47687 3
Other Medicine Technology:Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus 2Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus 3Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus 4Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 2CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 3CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 4CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 6CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 7CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 8CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 9CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 10